Research programme: lorazepam transmucosal spray - EastGate Biotech

Drug Profile

Research programme: lorazepam transmucosal spray - EastGate Biotech

Alternative Names: Lorazepam transmucosal oral spray - EastGate Biotech

Latest Information Update: 21 Jan 2016

Price : $50

At a glance

  • Originator EastGate Acquisitions
  • Developer EastGate Biotech
  • Class Antiemetics; Anxiolytics; Benzodiazepinones; Hypnosedatives; Small molecules
  • Mechanism of Action GABA A receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Seizures

Most Recent Events

  • 19 Jan 2016 EastGate receives notice of publication for two patents covering lorazepam transmucosal spray in USA
  • 03 Feb 2015 East Gate has patent protection for lorazepam transmucosal spray
  • 15 Dec 2014 EastGate Biotech is now EastGate Acquisitions
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top